4.87
price down icon3.75%   -0.19
 
loading
Schlusskurs vom Vortag:
$5.06
Offen:
$4.97
24-Stunden-Volumen:
10,947
Relative Volume:
0.55
Marktkapitalisierung:
$26.87M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-21.81M
KGV:
-6.3247
EPS:
-0.77
Netto-Cashflow:
$-16.66M
1W Leistung:
-10.64%
1M Leistung:
+2.53%
6M Leistung:
-23.31%
1J Leistung:
+5.14%
1-Tages-Spanne:
Value
$4.5715
$4.99
1-Wochen-Bereich:
Value
$4.5715
$5.69
52-Wochen-Spanne:
Value
$3.7728
$8.48

Pluri Inc Stock (PLUR) Company Profile

Name
Firmenname
Pluri Inc
Name
Telefon
972-74-710-7171
Name
Adresse
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Name
Mitarbeiter
118
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
PLUR's Discussions on Twitter

Vergleichen Sie PLUR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
PLUR 4.84 26.87M 598.00K -21.81M -16.66M -0.77
VRTX 450.27 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.65 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.61 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.57 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.17 24.89B 3.30B -501.07M 1.03B 11.54

Pluri Inc Aktie (PLUR) Neueste Nachrichten

pulisher
Nov 15, 2024

Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024) - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - StreetInsider.com

Nov 14, 2024
pulisher
Nov 14, 2024

BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 12, 2024

Pluri: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle

Nov 12, 2024
pulisher
Nov 12, 2024

Pluri (PLUR) to Present at Q4 Virtual Investor Summit: Biotech Showcase for Growth | PLUR Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Pluri (PLUR) Announces Key Collaboration, Driving Stock Upward - Stocks Telegraph

Nov 12, 2024
pulisher
Nov 11, 2024

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire

Nov 11, 2024
pulisher
Nov 11, 2024

BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | PLUR Stock News - StockTitan

Nov 11, 2024
pulisher
Oct 28, 2024

Pluri And Bar-Ilan University Partner To Advance MAIT Cell Therapy For Solid Tumors - Contract Pharma

Oct 28, 2024
pulisher
Oct 28, 2024

Pluri Flat on Funding From Innovation Authority - Baystreet.ca

Oct 28, 2024
pulisher
Oct 28, 2024

Pluri Collaborates with Bar-Ilan University to Advance - GlobeNewswire

Oct 28, 2024
pulisher
Oct 28, 2024

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority - StockTitan

Oct 28, 2024
pulisher
Oct 25, 2024

Cell And Gene Therapy Contract Development And Manufacturing - openPR

Oct 25, 2024
pulisher
Oct 14, 2024

Renaissance Technologies LLC Decreases Position in Pluri Inc. (NASDAQ:PLUR) - Defense World

Oct 14, 2024
pulisher
Oct 05, 2024

(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 03, 2024

Plurilock (PLUR.V) lands $19 million deal, largest in their history - Equity.Guru

Oct 03, 2024
pulisher
Oct 01, 2024

Pluri Inc. regains compliance with Nasdaq listing rules - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Pluri Inc. regains compliance with Nasdaq listing rules By Investing.com - Investing.com UK

Oct 01, 2024
pulisher
Sep 30, 2024

Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Sep 30, 2024
pulisher
Sep 26, 2024

TomTom (OTCMKTS:TMOAF) Short Interest Down 34.8% in September - Defense World

Sep 26, 2024
pulisher
Sep 14, 2024

(PLUR) Proactive Strategies - Stock Traders Daily

Sep 14, 2024
pulisher
Sep 13, 2024

The Plurilock (PLUR.V) rip is over: But is that the end of the play? - Equity.Guru

Sep 13, 2024
pulisher
Sep 12, 2024

Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive

Sep 12, 2024
pulisher
Sep 11, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance

Sep 11, 2024
pulisher
Sep 04, 2024

Plurilock Security joins forces with cloud platform for data protection - Mugglehead

Sep 04, 2024
pulisher
Aug 29, 2024

Cell Therapy Manufacturing Market Size Projected to Reach - GlobeNewswire

Aug 29, 2024
pulisher
Aug 13, 2024

Ever After Foods receives $10 million investment - Food Business News

Aug 13, 2024
pulisher
Aug 09, 2024

Former CrowdStrike Director Reveals Plurilock’s Potential - The Deep Dive

Aug 09, 2024
pulisher
Aug 08, 2024

Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace

Aug 08, 2024
pulisher
Aug 04, 2024

Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma

Aug 04, 2024
pulisher
Aug 01, 2024

Cyber Warfare: Ex-CIA Officer Warns of New Global Conflict, With Bryan Cunningham of Plurilock Security - The Deep Dive

Aug 01, 2024
pulisher
Jul 30, 2024

Pluri (NASDAQ:PLUR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Review - American Banking and Market News

Jul 30, 2024
pulisher
Jul 27, 2024

(PLUR) Trading Advice - Stock Traders Daily

Jul 27, 2024
pulisher
Jul 27, 2024

Critical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR) - Defense World

Jul 27, 2024
pulisher
Jul 25, 2024

Spanish seafood processors slam plant-based seafood labeling practices; Steakholder Foods signs MoU with Sherry Herring - SeafoodSource

Jul 25, 2024
pulisher
Jul 25, 2024

Spanish seafood processors slam plant-based seafood labeling practices; Tender Food products now in Clover locations - SeafoodSource

Jul 25, 2024
pulisher
Jul 23, 2024

Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com

Jul 23, 2024
pulisher
Jul 23, 2024

Pluri Inc. faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

Jul 23, 2024
pulisher
Jul 22, 2024

400% Stock Surge: What’s Next for Plurilock Security? | Ali Hakimzadeh - The Deep Dive

Jul 22, 2024
pulisher
Jul 22, 2024

Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS - ALS News Today

Jul 22, 2024
pulisher
Jul 19, 2024

Pluri signs tech transfer, manufacturing agreement with Kadimastem - TipRanks

Jul 19, 2024
pulisher
Jul 18, 2024

Pluri’s CDMO To Manufacture Kadimastem’s Cell Therapy Candidates - Contract Pharma

Jul 18, 2024
pulisher
Jul 18, 2024

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - Morningstar

Jul 18, 2024
pulisher
Jul 17, 2024

(PLUR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jul 17, 2024
pulisher
Jul 17, 2024

Joe Sexton: Enhancing Plurilock’s Vision with Decades of Experience - The Deep Dive

Jul 17, 2024
pulisher
Jul 16, 2024

Contrasting Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - American Banking and Market News

Jul 16, 2024
pulisher
Jul 15, 2024

Plurilock Appoints Palantir Senior Advisor To Company’s Industry Advisory Council - The Deep Dive

Jul 15, 2024
pulisher
Jul 14, 2024

Critical Comparison: Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - Defense World

Jul 14, 2024
pulisher
Jul 10, 2024

Pluri (NASDAQ:PLUR) Trading 0.3% Higher - Defense World

Jul 10, 2024
pulisher
Jul 09, 2024

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs - Business Wire

Jul 09, 2024
pulisher
Jul 08, 2024

Pluri Inc partners to boost global vegetable supply - Investing.com India

Jul 08, 2024

Finanzdaten der Pluri Inc-Aktie (PLUR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):